Please use this identifier to cite or link to this item:
Title: Converging Evidence Points to BDNF as Biomarker of Depressive Symptoms in Schizophrenia-Spectrum Disorders
Authors: Manchia, Mirko
Isayeva, Ulker
Collu, Roberto
Primavera, Diego
Deriu, Luca
Caboni, Edoardo
Iaselli, Maria Novella
Sundas, Davide
Tusconi, Massimo
Pinna, Federica
Paribello, Pasquale
Scherma, Maria
Pisanu, Claudia
Meloni, Anna
Zai, Clement C.
Congiu, Donatella
Squassina, Alessio
Fratta, Walter
Fadda, Paola
Carpiniello, Bernardo
Keywords: BDNF
schizoaffective disorder
Issue Date: 4-Dec-2022
Publisher: MDPI
Citation: Brain Sciences
Series/Report no.: Vol. 12;№ 12
Abstract: Brain-derived neurotrophic factor (BDNF) is a key modulator of neuroplasticity and has an important role in determining the susceptibility to severe psychiatric disorder with a significant neurodevelopmental component such as major psychoses. Indeed, a potential association between BDNF serum levels and schizophrenia (SCZ) and schizoaffective disorder (SAD) has been tested in diverse studies and a considerable amount of them found reduced BDNF levels in these disorders. Here, we aimed at testing the association of BDNF serum levels with several demographic, clinical, and psychometric measures in 105 patients with SCZ and SAD, assessing the moderating effect of genetic variants within the BDNF gene. We also verified whether peripheral BDNF levels differed between patients with SCZ and SAD. Our findings revealed that BDNF serum levels are significantly lower in patients affected by SCZ and SAD presenting more severe depressive symptomatology. This finding awaits replication in future independent studies and points to BDNF as a possible prognostic indicator in major psychoses.
ISSN: 2076-3425
Appears in Collections:Publications

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.